posted on
Mar 31, 2009 09:53AM
Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: KTOS
From the KTOS 10k...
We issued 25.3 million shares to SYS shareholders in the merger, for a total purchase price of $55.9 million including direct transaction costs of $2.4 million.
Revenues increased $103.7 million from $193.6 million in 2007 to $297.3 million in 2008, reflecting an increase of $104.2 million in our Kratos Government Solutions segment, primarily due to the acquisitions of Haverstick on December 31, 2007 and SYS on June 28, 2008. Haverstick revenue in 2008 was $85.5 million and SYS revenue was $33.2 million
We identified three business units of SYS that were not core to our business strategy and/or have been dilutive to profitability. The divestiture of these businesses will slightly reduce revenues going forward, and will immediately increase profitability and cash flow.
KTOS got back 60% of what they paid for SYS in only 6 mos...but immediately identifed and divested, from the SYS purchase, one of the SYS entities that we just bought...and the stated reason is..... immediate increase in profit with a small loss in revenue...smart business move for KTOS.
Now all we need to know is this an additional piece of the puzzle that we needed and if it is, then what are the effects on our revenue and profitablity from this acquisition?
Will see if it is mentioned in the Q as recent news since the quarter ending.
3 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply